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Abstract
Rationale—Patients with acute ischemic stroke and hyperglycemia have worse outcomes than
those without hyperglycemia. Intensive glucose control during acute stroke is feasible and can be
accomplished safely, but has not been fully assessed for efficacy.
Aims—The Stroke Hyperglycemia Insulin Network Effort (SHINE) trial aims to determine the
safety and efficacy of standard versus intensive glucose control with insulin in hyperglycemic
acute ischemic stroke patients.
Design—SHINE is a randomized, blinded, multicenter, Phase III trial of approximately 1400
hyperglycemic patients who receive either standard sliding scale subcutaneous insulin (blood
glucose range 80–179 mg/dL, 4.44–9.93 mmol/L) or continuous intravenous insulin (target blood
glucose 80–130 mg/dL, 4.44–7.21 mmol/L), starting within 12 hours of stroke symptom onset.
Study treatment lasts for up to 72 hours. The acute treatment phase is single-blind (for the
patients), but the final outcome assessment is double-blind. The study is powered to detect a 7%
absolute difference in favorable outcome at 90 days.
Study outcomes—The primary outcome is a baseline severity adjusted 90 day modified Rankin
Scale (mRS) score. Favorable outcome is defined as mRS=0 if the baseline NIH Stroke Scale
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(NIHSS) is 3–7, or mRS≤1 if the baseline NIHSS is 8–14, or mRS≤2 if the baseline NIHSS is 15–
22. The primary safety outcome is the rate of severe hypoglycemia (<40 mg/dL, <2.22 mmol/L).
Discussion—This trial will provide important novel information about preferred management of
acute ischemic stroke patients with hyperglycemia. It will determine the potential benefits and
risks of intensive glucose control during acute stroke.
Keywords
acute ischemic stroke; cerebral infarction; clinical trial; ischemic stroke; protocols; stroke;
hyperglycemia; diabetes
Introduction and rationale
Hyperglycemia is seen in approximately 40% of acute ischemic stroke patients1, 2 and is
associated with worse clinical outcomes.1–3 Preclinical and clinical data suggest a potential
clinical benefit of intensive glucose control in the setting of acute cerebral ischemia.
However, hypoglycemia, especially severe or prolonged hypoglycemia, is of greatest
concern with insulin therapy.4–7 A protocol minimizing severe and prolonged hypoglycemia
while controlling hyperglycemia has the potential to improve outcomes in acute stroke
patients. Intensive glucose control with IV insulin therapy has been found to improve
clinical outcomes in some non-stroke acute illnesses.8, 9 However, there remains clinical
equipoise about how best to treat hyperglycemia during acute ischemic stroke. Results from
the National Institutes of Health (NIH)/National Institute of Neurological Disorders and
Stroke (NINDS) funded Treatment of Hyperglycemia in Ischemic Stroke (THIS)10 and the
Glucose Regulation in Acute Stroke Patients (GRASP) 11 trials demonstrated safety and
feasibility of insulin infusion therapy for intensive glucose control in acute ischemic stroke
patients. No previous trial has fully assessed the efficacy of intensive glucose control and
current stroke guidelines therefore emphasize the need for definitive clinical trials to
determine optimal management of hyperglycemia in acute stroke.12
As improved glucose control protocols decreased the risk of hypoglycemia, determining the
efficacy and safety of intensive versus standard glucose control in acute ischemic stroke
patients became a priority. Numerous previous glucose control trials informed the SHINE
trial design.10, 11, 13–15 The SHINE trial was designed to address key questions about
hyperglycemia management in acute stroke. The primary aim of the SHINE trial is to
determine the efficacy of intensive versus standard glucose control. The secondary aim is to
assess safety and therefore determine an overall risk/benefit profile for the intensive insulin
intervention versus the standard treatment. The results of this trial will likely clarify the
preferred treatment and guide clinical decision making.
Design
SHINE is a randomized, blinded, multicenter, controlled phase III trial of continuous
intravenous insulin versus standard subcutaneous insulin in acute ischemic stroke with
hyperglycemia. Additional treatments constituting usual care are allowed; including
intravenous (IV) tissue plasminogen activator (tPA), intraarterial tPA, and United States
Food and Drug Administration cleared endovascular devices. Throughout the study period,
current American Heart Association guideline for the early management of adults with
ischemic stroke will be followed.12
Enrollment must be within 12 hours of stroke symptom onset. Also, to maximize early
treatment, enrollment should be within 3 hours of arrival to the Emergency Department. The
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12 hour window for enrollment is based on a combination of supporting animal model data,
feasibility, and generalizability considerations.
The trial is single blind during treatment and double blind for the functional outcome
assessment. Blinding the treating team during treatment was felt to impose excessive risk,
and having an unblinded investigator manage the study treatment for 72 hours on an hourly
basis is not feasible.
At 6 weeks serious adverse events and early follow-up information are assessed by
telephone. At 3 months the primary and secondary outcomes are assessed in-person.
Subjects unable to return in-person at 3 month are assessed by telephone. The sliding
dichotomy that assesses the primary outcome allows individual patients to have favorable
outcomes according to their initial stroke severity, based on the NIHSS.16 This design
maximizes the generalizability of the results by enrolling a broad range of stroke severities,
and increases the use of individual patient data that are often lost with single dichotomized
outcome definitions. The sliding dichotomy has been successfully used in a previous stroke
trial17 and is described under primary outcome.
Recruitment is aimed at capturing a broad patient population from across the United States
with expected suitable representation of women and minorities (see appendix). Only adults
aged 18 years or older are included. To optimize recruitment, the SHINE research team
includes a Recruitment PI (CEH) and a NINDS Recruitment Specialist whose focus is to
maximize timely recruitment across all sites. This team has developed individualized
screening and recruitment goals and a monitoring plan for each site. The recruitment plan is
designed to promptly and accurately estimate the number of sites required to complete
recruitment on schedule.
The limitations of this design include potential bias due to the single-blind acute treatment
period. The double-blind primary outcome assessment is designed to eliminate this bias.
Potential measured and unmeasured confounders include all treatments and care outside the
study treatment protocol through the 90 day outcome assessment. The secondary analysis
will attempt to adjust for pre-specified confounds.
Patient population
The primary target population for the SHINE trial are acute ischemic stroke patients likely
to have persistent hyperglycemia during hospitalization, and who can be enrolled within 12
hours of symptom onset (Table 1). Patients receiving standard IV tPA are stratified at
randomization to prevent confounding of treatment effect.
Previous data indicate that patients with history of type 2 diabetes or those with baseline
blood glucose at or above 150 mg/dL (8.32 mmol/L)(even without diabetes) are likely to
have persistent hyperglycemia, unless treated with insulin.10, 11, 13, 18 Patients who do not
meet these criteria typically have self-limited hyperglycemia that resolves early and
spontaneously during hospitalization.10, 13, 19 Thus, the SHINE eligibility criteria attempt to
exclude patients with self-limited hyperglycemia.
Previous data show that patients with the mildest strokes generally have good outcomes and
those with the most severe strokes generally have poor outcomes. Therefore, the mildest
(NIHSS <3) and most severe (NIHSS >22) stroke patients are excluded from the SHINE
trial to avoid obscuring a treatment difference between the groups. Also, excluded are
patients for whom clinical equipoise for treatment is absent (e.g., those with type 1 diabetes
or pregnancy), those at excessive risk from either intervention (e.g., receiving renal dialysis),
those at risk for loss to follow up (inability to return), and those with confounding that
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would preclude accurate estimation of treatment effect (other experimental interventions,
substantial pre-existing neurological or psychiatric disease) (Table 1).
Additionally, since with the sliding dichotomy some patients require a 90 day mRS of 0 to
classify as having favorable outcome, those with residual symptoms from prior stroke, or
who are unable to live independently due to pre-existing disabilities, are excluded from this
trial.
Randomization
The SHINE trial utilizes a web-based central randomization system that employs a
combination of covariate balance20 and response adaptive randomization (RAR)21 methods.
The prognostic variables considered at the time of randomization include baseline NIHSS
strata (3–7, 8–14, 15–22), use of IV tPA thrombolysis (yes/no), and clinical center.
Randomization is initially 1:1, but as the trial progresses this ratio may change based on two
factors, the prevention of serious imbalances in the pre-specified prognostic variables and
the favorable outcome rate in each treatment group. This randomization design is aimed to
preserve the randomness of treatment assignment, prevent serious imbalance in important
baseline prognostic variables, and promote subject recruitment while preserving the
statistical test power.
Treatment
There are two treatment groups in the SHINE trial (Table 2). One group receives continuous
IV insulin infusion to maintain blood glucose 80–130 mg/dL (4.44–7.21 mmol/L). An FDA
cleared computerized decision support tool, GlucoStabilizer®,22 (Alere Informatics
Solutions [AIS], Charlottesville, VA) recommends the insulin drip rate to maintain the
glucose in the target range. The other group receives only subcutaneous (SQ) insulin to
maintain blood glucose 80–179 mg/dL (4.44–9.93 mmol/L)(Table 2). The glucose values
are based on point of care capillary glucose testing. All patients are treated with a
combination of IV and SQ study medications, some of which are insulin and some are
normal saline to maintain the blind (Table 2). All pre-stroke anti diabetes medications are
held throughout the treatment period. All patients are treated in hospital units that support IV
insulin infusion. At the completion of the 72 hour study treatment period, the treating team
determines the subsequent standard care regimen. For patients who are ready for discharge
prior to 72 hours, the study medications are discontinued at least 6 hours prior to discharge.
If study treatment must be temporarily interrupted for standard care reasons, procedures for
pausing and restarting the study treatment are provided.
The treating nurses enter all glucose levels and insulin treatments in both groups into laptop
computers, which are instantly transmitted to an AIS server in Charlottesville, VA. AIS
transfers all study data to the Statistical and Data Management Center every 24 hours.
Hypoglycemia is defined as blood glucose <70 mg/dL (<3.88 mmol/L), and severe
hypoglycemia as <40 mg/dL (<2.22 mmol/L), but to prevent hypoglycemia, study
medications are held and IV glucose is given in both groups whenever the blood glucose
levels fall to <80 mg/dL (<4.44 mmol/L). In the control group, patients receive 25 ml of
50% dextrose (D50), glucose level is rechecked every 15 minutes and additional D50 is
given after each check until the glucose is ≥80 mg/dL (≥4.44 mmol/L). In the intervention
group, the GlucoStabilizer® program recommends a calculated dose of D50 based on the
blood glucose level.22 The computer sounds an alarm to recheck the glucose level every 15
minutes and recommends additional D50 doses until the glucose is ≥80 mg/dL (≥4.44 mmol/
L).
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When blood glucose is <70 mg/dL (<3.88 mmol/L) in either group, a confirmatory blood
sample is sent to the laboratory. Additionally, a hypoglycemia symptomatic questionnaire23
and a neurological examination are done every 15 minutes until resolution.
Primary outcome
The primary efficacy outcome is baseline severity adjusted 90 day mRS assessed using a
sliding dichotomy to identify favorable outcomes, also known as responder analysis.16 The
responder analysis dichotomizes mRS scores as favorable or unfavorable based on the
baseline NIHSS measured at enrollment and the 90 day mRS, and was chosen to provide a
more sensitive measure of clinical effect. Patients in the lowest baseline severity tertile
(NIHSS 3–7) need to have a 90 day mRS score of 0 to achieve favorable outcome. Patients
with baseline NIHSS 8–14 can have a 90 day mRS score 0–1 for favorable outcome, and
those with baseline NIHSS 15–22 can have a 90 day mRS score 0–2 for favorable outcome,
as used in previous trials.17
Secondary outcomes
Secondary outcomes include favorable outcome as measured by the NIHSS, Barthel Index
and the Stroke Specific Quality of Life scale24 at 90 days. Blood glucose control and
protocol adherence will also be analyzed.
Data and safety monitoring
Adverse events are collected during the study treatment period, and serious adverse events
are collected throughout the entire study period. The primary safety outcome is the rate of
severe hypoglycemia determined as the percentage of patients in each group having at least
one blood glucose measurement <40 mg/dL (<2.22 mmol/L) during the treatment period.
A study appointed independent safety monitor and an NIH-NINDS appointed Data and
Safety Monitoring Board (DSMB) oversee safety in the SHINE trial. The DSMB meets
every six months to review study progress and accumulated data. Their main responsibilities
are to ensure that study participants are not exposed to unnecessary or unreasonable risks,
and that the study is conducted with high scientific and ethical standards. The DSMB is
assisted by an independent safety monitor who reviews and adjudicates all serious adverse
events throughout the study. The independent safety monitor also fields safety concerns
from the investigators during study treatment.
Sample size
The sample size estimate was based on data from the two NIH funded pilot trials,10, 11 as
well as other relevant acute stroke trials.25, 26 These data supported an estimate of 25%
favorable outcome rate in the control group. The minimal clinically relevant absolute
difference in favorable outcome between the two treatment groups was estimated to be 7%
(control group = 25%; intervention group = 32%). The study is therefore powered to detect
an absolute 7% difference in favorable outcome between the groups. The study design
includes four interim analyses for both efficacy and futility of the primary outcome (after
500, 700, 900, and 1,100 patients complete the study) and a final analysis for a total of five
planned analyses of the primary outcome. Including a 3% non-adherence rate and the four
interim analyses, approximately 1400 randomized patients are needed to provide 80% power
with a two-sided type I error rate of 0.05.
In the event that the control group favorable outcome rate is higher than 25% a blinded
sample size re-estimation will be done prior to the first interim efficacy/futility analysis
Bruno et al. Page 5
Int J Stroke. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
using the approach of Gould and Shih.27 The overall favorable outcome rate of the study
population will be estimated using the interim data for the sole purpose of sample size re-
estimation (not for interim testing of a treatment effect).
Statistical analysis
The primary analysis for the SHINE trial will compare the proportion of subjects in each
treatment group with favorable outcome after controlling for baseline NIHSS and standard
IV tPA. Outcome differences will be analyzed under the intention-to-treat principle (all
randomized participants included) and adjusted relative risks will be reported with two-sided
95% confidence intervals. Additional analyses will identify potential prognostic variables as
covariates for secondary analyses of the primary outcome. Specific variables include age,
gender, race, ethnicity, admission blood glucose, previous stroke, lacunar stroke subtype,
and time from stroke onset to randomization.
The four interim analysis plans described above use the error spending function method with
O’Brien and Fleming (OBF) type stopping guidelines.28, 29 The OBF-type boundary is
considered conservative as its boundaries make it unlikely to terminate a study early by
requiring overwhelming early evidence of efficacy or futility. It spends smaller amounts of
alpha at the first look and gradually increases the spending as more information is acquired
while maintaining the overall type I and II error rates. For example, under the null
hypothesis of no difference between the two treatment groups, there is a 4% chance of
stopping the trial for futility at the first look, 10% at the second, 25% at the third, and 35%
at the fourth. Overall, there is approximately a 75% chance of stopping the trial early for
futility, if there is no difference. Under the alternative hypothesis, there is an 11% chance of
stopping the trial early for overwhelming efficacy at the first look, and a 66% chance overall
of stopping early. These analyses will begin once final outcome data are available from
roughly one-third of the study population.
Trial organization and funding
The SHINE trial is funded by the NIH/NINDS. Recognizing the effort and skill needed to
successfully run the various aspects of a large acute clinical trial, the SHINE trial has three
principal investigators, each with a specified focus. The administrative PI (KCJ) is the main
contact person for SHINE and chairs the executive committee. The protocol PI (AB)
oversees the treatment protocols. The recruitment PI (CH) is focused on patient recruitment
and retention. A study endocrinologist (RJ) oversees the insulin treatments and all relevant
metabolic issues. The SHINE trial is conducted primarily in collaboration with the NINDS
funded Neurological Emergencies Treatment Trials (NETT) Network, as well as numerous
ancillary (non-NETT) sites for patient enrollment. The NETT includes 22 hub and spoke
complexes (Appendix) (NETT PI is WB). The Clinical Coordinating Center for the NETT,
and therefore SHINE, is at the University of Michigan. The Statistical and Data
Management Center for the NETT and for SHINE is the Medical University of South
Carolina Data Coordinating Unit, directed by the SHINE Statistical PI (VLD). A total of
approximately 60 sites are expected to participate in this trial.
Summary
The SHINE trial is designed to address key questions about the management of
hyperglycemia during acute ischemic stroke. This trial has the potential to impact the
management of a substantial proportion of acute stroke patients. This trial design is
scientifically rigorous, including response adaptive randomization and baseline severity
adjusted double-blind primary outcome assessment. Continuous intravenous insulin infusion
based on a computerized decision support tool will be compared to a standard subcutaneous
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insulin sliding scale. Recruitment started in April 2012 and is expected to be completed in
2016.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Addendum
After enrolling 57 patients, the SHINE DSMB approved a protocol modification allowing
enrollment of patients with a pre-stroke mRS of 0 or 1 if their baseline NIHSS is 8–22.
However, patients with baseline NIHSS 3–7 must have a pre-stroke mRS of 0 to permit
reaching a potential favorable outcome that is based on a sliding dichotomy of the mRS
according to the baseline NIHSS score.
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Table 1
Eligibility criteria
Inclusion
1 Age 18 years or older
2 Clinical diagnosis of ischemic stroke. Neuroimaging must be done to exclude intracranial hemorrhage.
3 Protocol treatment must begin within 3 hours after hospital arrival and within 12 hours after stroke symptom onset. If time of
symptom onset is unclear or patient is awakening with stroke symptoms, the time of onset will be the time that the patient was last
known to be normal.
4 Known history of type 2 diabetes mellitus and admission blood glucose >110 mg/dL (>6.10 mmol/L) OR admission blood glucose
≥150 mg/dL (≥8.32 mmol/L) in those without known diabetes mellitus.
5 Baseline NIHSS score 3–22.
6 Pre-stroke modified Rankin Scale score = 0 (able to walk, look after own affairs, and no residual symptoms from prior stroke).
7 Able to provide a valid informed consent to enroll (self or legally authorized representative).
Exclusion
1 History of type 1 diabetes mellitus.
2 Substantial pre-existing neurological or psychiatric illness that could confound the neurological or other outcome assessment.
3 Having received experimental therapy for the enrollment stroke. IV tPA up to 4.5 hours or IA tPA are allowed as are endovascular
therapies using FDA cleared devices. Non-FDA cleared devices are considered experimental and are excluded.
4 Known to be currently pregnant or breast-feeding.
5 Unlikely to survive 90 days due to another serious condition.
6 Inability to follow the protocol or return for the 90 day follow up.
7 Renal dialysis, including hemo- or peritoneal.
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Table 2
Outline of subcutaneous and intravenous study treatments in the SHINE protocol.
Control Group Intensive Treatment Group
Subcutaneous treatments
Regular human insulin at 6:00, 12:00, 18:00 and at 24:00
according to sliding scale;
At 24 and 48 hours advance to the next treatment level if
the latest 2 glucose levels are ≥180 mg/dL;
Level 1 sliding scale: 2–8 units for glucose 180 to >450
mg/dL;
Level 2 sliding scale: 4–16 units for glucose 180 to >450
mg/dL
Level 3 sliding scale: same as level 2 plus long acting basal
insulin (glargine*) at 48 hours
If not eating or continuous tube feeding,
normal saline (placebo) at 9:00 and 21:00,
or
If eating or bolus tube meals, rapid acting
analog insulin with meals
Intravenous treatments Normal saline (placebo) with periodic rate adjustments Continuous regular human insulin according to
a computerized tool, GlucoStabilizer®.
Capillary blood glucose
monitoring
Every 1 hour for the first 4 hours, then 3:00, 6:00, 9:00,
12:00, 15:00, 18:00, 21:00, and 24:00 (before meals if
patient is eating)
Every 1–2 hours according to
GlucoStabilizer® instructions
*dose of glargine insulin is 40% of the total insulin given in the prior 24 hours;
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